SMS Pharmaceuticals Reports 48% PAT Growth in FY26, Driven by Backward Integration and API Focus
SMS Pharmaceuticals Limited, an integrated pharmaceutical company specializing in Active Pharmaceutical Ingredients (API) and complex Intermediates for global customers, has announced its audited financial results for the fiscal year ended March 31, 2026.The company reported that its Profit After Tax (PAT) grew by 48% Year over Year (YoY) to reach ₹102 crore. This substantial increase was attributed to the benefits of backward integration and a favorable product mix. Furthermore, the EBITDA margin for FY26 saw a notable increase of 155 basis points (bps) YoY, reaching 19%, fueled by backward integration and operating leverage. Overall, strong performance across key APIs contributed to the company achieving 13% revenue growth in FY26.
The Board of Directors of SMS Pharmaceuticals Limited recommended a final dividend of ₹0.40 (40%) per share.
Strategic Performance Drivers
Commenting on the financial performance, Mr. P. Vamsi Krishna, Executive Director, highlighted that the results reflect the successful execution of the company's multi-year strategy. He noted that the focus on increasing backward integration and continuously diversifying the product portfolio has strengthened the competitive advantage.The company is strategically increasing its focus on segments such as anti-inflammatory and Anti-Retroviral (ARV) APIs, where the advantages of backward integration and scale are growing more apparent. While optimizing resource allocation by scaling back in areas with evolving dynamics, the company managed to deliver 13% revenue growth in FY26.
Mr. Krishna also pointed to the ongoing research and development efforts, noting the completion of 12 DMF and CEP filings in FY26, with plans to target 10 additional submissions in FY27.
VKT Pharma, the associate company, contributed a healthy ₹14 crore to the FY26 PAT. The company anticipates this contribution to remain sustainable and strengthen into FY27.
Financial Summary and Key Data Points
The company's performance review highlights significant growth in the overall financials for FY26.| Particulars | Q4FY26 | Q4FY25 | YoY Growth (%) | FY26 | FY25 | YoY Growth (%) |
|---|---|---|---|---|---|---|
| Revenue from operations | 237.95 crore | 248.20 crore | -4% | 886.87 crore | 782.75 crore | 13% |
| Gross profit | 81.29 crore | 76.46 crore | 6% | 302.83 crore | 264.70 crore | 14% |
| Gross profit margin | 34% | 31% | 336 bps | 34% | 34% | 33 bps |
| EBITDA | 39.90 crore | 40.82 crore | -2% | 171.28 crore | 139.00 crore | 23% |
| EBITDA margin | 17% | 16% | 32 bps | 19% | 18% | 155 bps |
| PAT | 32.71 crore | 20.32 crore | 61% | 101.98 crore | 69.14 crore | 47% |
| PAT margin | 14% | 8% | 556 bps | 11% | 9% | 267 bps |
In the fourth quarter of FY26, the gross margin expanded by 336 bps YoY to 34%. For the full year, EBITDA grew 23% YoY, with the EBITDA margin expanding 155 bps YoY to 19%.
Revenue Contribution by Therapeutic Area
The revenue breakdown illustrates the strategic shift in the product mix, with Anti-Retroviral (ARV) and Anti-inflammatory segments leading growth.| Particulars | FY26 Revenue (₹ Cr) | As % of Total Revenue | FY25 Revenue (₹ Cr) | As % of Total Revenue | YoY Growth (%) |
|---|---|---|---|---|---|
| Anti Retro Viral (ARV) | 251.80 | 28% | 162.83 | 21% | 55% |
| Anti-inflammatory | 177.05 | 20% | 147.63 | 19% | 20% |
| Anti-diabetic | 129.40 | 15% | 185.38 | 24% | -30% |
| Anti-migraine | 93.81 | 11% | 96.16 | 12% | -2% |
| Anti-ulcer | 46.02 | 5% | 55.64 | 7% | -17% |
| Anti-erectile dysfunction | 53.68 | 6% | 48.92 | 6% | 10% |
| Anti-epileptic | 54.15 | 6% | 29.21 | 4% | 85% |
| Anti-anginal | 41.52 | 5% | 24.38 | 3% | 70% |
| Others | 39.44 | 4% | 32.60 | 4% | 21% |
Future Outlook and Capex
The company confirmed that the ₹280 crore capacity expansion programme is on track for completion by FY27. These investments are set to enhance capacity for existing APIs, build capacity for new product pipelines, and expand the R&D capabilities.Management remains positive on the future outlook, projecting over 15% revenue growth and maintaining EBITDA margins in the range of 20% in FY27. This growth is anticipated to be supported by the increasing contribution from high-margin APIs, continued benefits from backward integration, and capacity expansion.
SMS Pharmaceuticals Limited, established in 1990, operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 200 KL and 3,000 KL, respectively. The company serves a global customer base in over 70 countries.
SMSPHARMA Stock Price Movement
On Friday, SMS Pharmaceuticals Limited shares slipped by 10.41% to settle at ₹381.45. The stock saw significant trading activity, with 2.13 million shares transacting throughout the previous session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.